HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Gastroenterology · H2 Antagonist Competitive Landscape

Intelligence report

Intelligence Report · ~14 min read

Gastroenterology · H2 Antagonist Competitive Landscape

4 findings · 54 signals · 6 insights

Type

Competitive Landscape Report

Generated

Jul 23, 2026

Confidence

High Confidence · 92%

Evidence

58 items

Sources

1

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Competitive landscape assessment for Gastroenterology · H2 Antagonist synthesizes 4 Competitiva findings across 54 active signals. 1 high-pressure competitive threats identified. 8 companies maintain material exposure in this therapeutic area.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. competitive

    Merck — Mirikizumab

    Merck is a direct competitive threat because it has a Phase III program in Gastroenterology · Ulcerative Colitis (Mirikizumab) and could narrow Lilly's development lead.

    View detail
  2. competitive

    Merck — Afimkibart

    Merck is a direct competitive threat because it has a Phase III program in Gastroenterology · Ulcerative Colitis (Afimkibart) and could narrow Roche's development lead — particularly against Afimkibart.

    View detail
  3. competitive

    Merck — Vixarelimab

    Merck is a direct competitive threat because it has a Phase III program in Gastroenterology · Ulcerative Colitis (Vixarelimab) and could narrow Roche's development lead.

    View detail
  4. competitive

    Merck — Tofacitinib

    Merck is a direct competitive threat because it has a Phase III program in Gastroenterology · Ulcerative Colitis (Tofacitinib) and could narrow Pfizer's development lead.

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Monitor 1 high-pressure competitive programs for portfolio displacement risk. Cross-reference 6 executive insights for synthesized strategic assessment. Leading competitive pressure: Medium across top-linked programs.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Merck — Mirikizumab

    95%

    Merck is a direct competitive threat because it has a Phase III program in Gastroenterology · Ulcerative Colitis (Mirikizumab) and could narrow Lilly's development lead.

    Source: Merck

    View evidence

  • Merck — Afimkibart

    83%

    Merck is a direct competitive threat because it has a Phase III program in Gastroenterology · Ulcerative Colitis (Afimkibart) and could narrow Roche's development lead — particularly against Afimkibart.

    Source: Merck

    View evidence

  • Merck — Vixarelimab

    95%

    Merck is a direct competitive threat because it has a Phase III program in Gastroenterology · Ulcerative Colitis (Vixarelimab) and could narrow Roche's development lead.

    Source: Merck

    View evidence

  • Merck — Tofacitinib

    95%

    Merck is a direct competitive threat because it has a Phase III program in Gastroenterology · Ulcerative Colitis (Tofacitinib) and could narrow Pfizer's development lead.

    Source: Merck

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • Domperidone Updated with New Contraindication for Phaeochromocytoma Patients

    Label Change

  • FDA Accepts Supplemental NDA for Linzess by AbbVie

    Regulatory Approval

  • Phase III Trial of Afimkibart Shows Promise for Moderately to Severely Active Crohn's Disease

    Trial Update

  • Phase III Trial of Afimkibart Shows Promise for Ulcerative Colitis

    Trial Update

  • Merck's Tulisokibart Achieves Key Endpoints in Phase 3 UC Study

    Trial Update

  • Pfizer's Phase 3 Study of Tofacitinib in Pediatric Ulcerative Colitis Underway

    Trial Update

  • Study Compares Topical Anesthesia to Propofol-Ketamine for GI Endoscopy

    Trial Update

  • Aurobindo Pharma's ANDA213511 for Eluxadoline Receives AP Status

    Regulatory Approval

Insights

  • IL-37 as a Strategic Target in Colorectal Cancer and IBD Therapies

    Gastroenterology · Inflammatory Bowel Disease

  • Ustekinumab's Potential Expansion in Pediatric IBD Amidst Competitive Pressures

    Gastroenterology · Inflammatory Bowel Disease

  • Cumberland Pharmaceuticals' Generic Lactulose Approval Intensifies Laxative Market Competition

    Gastroenterology · Laxative

  • Regulatory Approvals for Proton Pump Inhibitors Signal Competitive Shifts

    Gastroenterology · Proton Pump Inhibitor

  • Emerging Competitive Landscape in Ulcerative Colitis Treatments: Merck vs.

    Gastroenterology · Ulcerative Colitis

  • Emerging Competitive Dynamics in Ulcerative Colitis Treatments and Diagnostics

    Gastroenterology · Ulcerative Colitis

Companies

  • Roche

    212 signals

  • Pfizer

    140 signals

  • Merck

    132 signals

  • Eli Lilly

    78 signals

  • Janssen

    36 signals

  • AbbVie

    26 signals

  • Aurobindo Pharma

    28 signals

  • Lupin

    13 signals

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.